|Bid||11.03 x 1000|
|Ask||11.22 x 800|
|Day's Range||11.01 - 11.65|
|52 Week Range||5.23 - 19.75|
|Beta (5Y Monthly)||0.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 17, 2021 - Feb 22, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.29|
BETHLEHEM, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, and microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will speak to the investment community at the Stephens Annual Investment Conference 2020. The conference will be simultaneously webcast over the Internet. Dr. Tang is scheduled to speak on November 19, 2020, at approximately 8:00 AM Eastern Standard Time (5:00 AM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com and clicking on the Investor Info link. A replay of the webcast will be available on OraSure Technologies’ web site for seven days. Alternatively, you can access the live webcast of the presentation via the following link: https://kvgo.com/stephens/orasure-november-2020 About OraSure TechnologiesOraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, CoreBiome (now operating under the Diversigen brand), UrSure and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.Company contacts: Sam Martin Argot Partners 212-600-1902 OraSure@argotpartners.comJeanne Mell VP Corporate Communications 484-353-1575 firstname.lastname@example.org www.orasure.com
Orasure Technologies just met that criteria with a new score of 85. When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. Orasure Technologies earns the No. 51 rank among its peers in the Medical-Products industry group.
Today, Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it has begun selling its best-in-class CRL Rapid Response™ saliva-based COVID-19 RT-PCR test directly to consumers. At $110 (which includes the cost of prepaid FedEx Priority Overnight shipping in both directions), the easy-to-use, highly accurate test is one of the most affordable COVID-19 home tests currently available in the market and the least expensive at-home saliva test.